Biotech CEOs are now more concerned about insurers than the Food and Drug Administration's regulatory process, reports Luke Zimmerman at Xconomy, drawing on a new survey put out by BayBio, the California Healthcare Institute, and PwC of 157 biotech CEOs in California.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Another Go-Round?

Investment Boom

GINA Not Enough?

Still Concerns

DNA or Pap?

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.